Ad
related to: new medication that builds bone marrow cancer- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Search results
Results from the WOW.Com Content Network
British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its oral therapy to treat anemia in patients with a type of bone marrow cancer called myelofibrosis. The ...
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...
Astellas' oral tablet Xospata's wholesale acquisition cost is $22,500 for a month's supply, while the list price of Novartis' Rydapt is $7,495 for a 14-day treatment and $14,990 for a 28-day ...
Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in many bones of the body. [7] This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts. [7]
Plerixafor has been found to be a strong inducer of mobilization of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells. [11] Additionally, plerixafor inhibits CD20 expression on B cells by interfering with CXCR4/SDF1 axis that regulates its expression.
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. [4] It was developed by Ariad Pharmaceuticals .
The drug, Vonjo (pacritinib), belongs to a class of anti-inflammatory treatments called JAK inhibitors, and will compete with Incyte Corp's Jakafi and Bristol Myers' Inrebic, which were approved ...
The idea for high-dose chemotherapy (HDC) with autologous bone marrow transplant (ABMT) originated in the 1950s as a leukemia treatment, when E. Donnall Thomas had shown that bone marrow could be harvested from a person and transplanted into the same or another person. [2] It was promoted as a treatment for advanced breast cancer starting in ...
Ad
related to: new medication that builds bone marrow cancer